Literature DB >> 27803050

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy.

Lorenzo Galluzzi1,2,3,4,5,6, Laurence Zitvogel6,7,8,9, Guido Kroemer10,3,4,5,11,12,13.   

Abstract

Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents-including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy-depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunostimulatory effects can be "on-target," i.e., they originate within cancer cells, or "off-target," i.e., they develop from a heretofore unsuspected interaction between cancer therapy and the immune system. Here, we briefly discuss the immunologic mechanisms that underlie the efficacy of some forms of cancer therapy, as we highlight the rationale for combining these treatment modalities with immunotherapy to achieve superior therapeutic effects. Cancer Immunol Res; 4(11); 895-902. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27803050     DOI: 10.1158/2326-6066.CIR-16-0197

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  63 in total

1.  Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.

Authors:  Paul J Bröckelmann; Helen Goergen; Ulrich Keller; Julia Meissner; Rainer Ordemann; Teresa V Halbsguth; Stephanie Sasse; Martin Sökler; Andrea Kerkhoff; Stephan Mathas; Andreas Hüttmann; Matthias Bormann; Andreas Zimmermann; Jasmin Mettler; Michael Fuchs; Bastian von Tresckow; Christian Baues; Andreas Rosenwald; Wolfram Klapper; Carsten Kobe; Peter Borchmann; Andreas Engert
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

Review 2.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?

Authors:  Andrea Riccardo Filippi; Jacopo Di Muzio; Serena Badellino; Cristina Mantovani; Umberto Ricardi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 4.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

Review 5.  Conditioning neoadjuvant therapies for improved immunotherapy of cancer.

Authors:  Zachary Benson; Saeed H Manjili; Mehran Habibi; Georgi Guruli; Amir A Toor; Kyle K Payne; Masoud H Manjili
Journal:  Biochem Pharmacol       Date:  2017-08-10       Impact factor: 5.858

Review 6.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

Review 7.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

Review 8.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 9.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 10.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.